May 28 2010
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, has dosed the first patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
“Dosing the first patient is a significant milestone for our company”
The clinical trial is slated to be a multicenter, randomized, placebo controlled, blinded clinical trial of ADXS11-001 -Advaxis' lead immunotherapeutic candidate. The dosing was administered at the site of Dr. Keith Aqua, M.D. of the Institute for Women's Health & Body.
"Dosing the first patient is a significant milestone for our company," commented Advaxis Chairman/CEO Thomas A. Moore. "It is a highly awaited development amongst all Advaxis and immunotherapy followers, at large; following the recent Dendreon Corporation (Nasdaq: DNDN) FDA approval. We look forward to completing and reporting the first dosing leg over approximately the next fifteen (15) months."
Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group